Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label phase III trial of Amphotericin B cholesteryl sulfate complex for invasive candidiasis and invasive aspergillosis
CTR20223158Phase 3Completed
- Sponsor
- CSPC Ouyi Pharmaceutical
- Start
- Dec 2022
- Modality
- Small Molecules, Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of amphotericin b cholesteryl sulfate complex in invasive candidiasis, invasive aspergillosis (IA) and deep fungal infection (IFI), sponsored by CSPC Ouyi Pharmaceutical. Primary endpoints: Treatment discontinuation due to study drug-related adverse events, Incidence of all study drug-related adverse events and safety assessments and 1 more. Started Dec 2022; status: completed.
02
Drugs
amphotericin b cholesteryl sulfate complex
03
Conditions
invasive candidiasisinvasive aspergillosis (IA)deep fungal infection (IFI)
Beyond the preview
Go deeper on CTR20223158.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20223158.